相关实验视频

Updated: Sep 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在非小细胞肺癌中EGFR^ins20的当前范式:前进的路还很长

Beatriz Viesser Miyamura¹, Isa Mambetsariev², Jeremy Fricke²

¹Dayan-Daycoval Family Hematology and Oncology Center, Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.

Med (New York, N.Y.)

|August 9, 2025

概括

肺癌中的EGFR外因子20插入 (EGFR^ins20) 突变以前的结果很差. 新的向疗法和FDA批准的药物,如amivantamab-vmjw为这些患者提供了更好的生存率.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

在5-12%的晚期非小细胞肺癌 (NSCLC) 患者中发生EGFR^ins20变化.
这些突变在历史上与预后不佳和对传统疗法反应有限相关.
以前针对EGFR的疗法在EGFR^ins20NSCLC中表现出有限的疗效.

研究的目的:

审查针对EGFR^ins20NSCLC的向治疗的不断变化的格局.
突出新药对患者结果和存活率的影响.
强调分子测试对于指导治疗决策的重要性.

主要方法:

对EGFR^ins20特定疗法的临床试验数据和FDA批准的审查.
对EGFR^ins20NSCLC患者治疗结果的分析.
讨论包括下一代测序 (NGS) 和液体活检在内的诊断方法.

主要成果:

新的向疗法显著改善了EGFR^ins20 NSCLC患者的治疗结果.
美国食品和药物管理局对amivantamab-vmjw和sunvozertinib的批准标志着治疗范式的转变.
目前正在进行的临床试验正在调查进一步的治疗选择.

结论:

针对EGFR^ins20的特定疗法代表了NSCLC精密医学的突破.
优先考虑NGS测试对于识别符合条件的患者和优化基于特定EGFR变异的治疗选择至关重要.
对EGFR^ins20NSCLC的治疗环境正在迅速发展,为改善生存提供了新的希望.

关键词:

欧洲农业基金 (EGFR) 在20年内临床试验中的临床试验.精准医学是一门精准医学.有针对性的治疗.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...